PL3531133T3 - Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b - Google Patents

Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b

Info

Publication number
PL3531133T3
PL3531133T3 PL18213926.1T PL18213926T PL3531133T3 PL 3531133 T3 PL3531133 T3 PL 3531133T3 PL 18213926 T PL18213926 T PL 18213926T PL 3531133 T3 PL3531133 T3 PL 3531133T3
Authority
PL
Poland
Prior art keywords
stratification
risk
lymphoblastic leukemia
acute lymphoblastic
leukemia patients
Prior art date
Application number
PL18213926.1T
Other languages
English (en)
Inventor
Gerhard Zugmaier
Peter Kufer
Shilpa ALEKAR
Original Assignee
Amgen Research (Munich) Gmbh
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3531133(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Research (Munich) Gmbh, Amgen Inc. filed Critical Amgen Research (Munich) Gmbh
Publication of PL3531133T3 publication Critical patent/PL3531133T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
PL18213926.1T 2014-05-30 2015-05-20 Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b PL3531133T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462005560P 2014-05-30 2014-05-30

Publications (1)

Publication Number Publication Date
PL3531133T3 true PL3531133T3 (pl) 2024-01-29

Family

ID=53284315

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18213926.1T PL3531133T3 (pl) 2014-05-30 2015-05-20 Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b
PL15727072T PL3149480T3 (pl) 2014-05-30 2015-05-20 Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15727072T PL3149480T3 (pl) 2014-05-30 2015-05-20 Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b

Country Status (18)

Country Link
US (1) US11079381B2 (pl)
EP (3) EP3149480B1 (pl)
AU (1) AU2015265578B2 (pl)
CA (1) CA2948771C (pl)
CY (1) CY1122600T1 (pl)
DK (2) DK3149480T3 (pl)
ES (2) ES2961565T3 (pl)
FI (1) FI3531133T3 (pl)
HR (1) HRP20231361T1 (pl)
HU (2) HUE063648T2 (pl)
LT (2) LT3531133T (pl)
PL (2) PL3531133T3 (pl)
PT (2) PT3531133T (pl)
RS (1) RS64773B1 (pl)
SI (2) SI3149480T1 (pl)
SM (1) SMT202300383T1 (pl)
TR (1) TR201903548T4 (pl)
WO (1) WO2015181683A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
SK286683B6 (sk) 1998-04-21 2009-03-05 Micromet Ag Polypeptidy špecifické pre CD19xCD3 a ich použitie
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
RS53905B1 (sr) 2005-12-16 2015-08-31 Amgen Research (Munich) Gmbh Metode i sredstva za lečenje tumorskih bolesti
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
SG195609A1 (en) 2007-04-03 2013-12-30 Amgen Res Munich Gmbh Cross-species-specific binding domain
HUE040467T2 (hu) 2007-04-03 2019-03-28 Amgen Res Munich Gmbh Keresztfaj-specifikus kötõdomén
CA2742249C (en) 2008-11-07 2020-07-21 Micromet Ag Treatment of acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody
RS53980B1 (sr) 2008-11-07 2015-10-30 Amgen Research (Munich) Gmbh Tretiranje akutne limfoblastne leukemije kod dece
PT2493503E (pt) 2009-10-27 2015-11-12 Amgen Res Munich Gmbh Regime de dosagem para administração de um anticorpo biespecífico cd19xcd3
CN103648529A (zh) 2011-04-28 2014-03-19 安进研发(慕尼黑)股份有限公司 用于给处于潜在不良反应的风险的患者施用CD19xCD3双特异性抗体的给药方案
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد

Also Published As

Publication number Publication date
WO2015181683A4 (en) 2016-02-04
CY1122600T1 (el) 2021-03-12
US20170122947A1 (en) 2017-05-04
AU2015265578B2 (en) 2021-09-02
EP3149480A1 (en) 2017-04-05
RS64773B1 (sr) 2023-11-30
US11079381B2 (en) 2021-08-03
HUE063648T2 (hu) 2024-01-28
WO2015181683A1 (en) 2015-12-03
SMT202300383T1 (it) 2024-01-10
CA2948771A1 (en) 2015-12-03
SI3531133T1 (sl) 2023-12-29
LT3149480T (lt) 2019-04-25
AU2015265578A1 (en) 2016-11-17
SI3149480T1 (sl) 2019-05-31
EP3531133A1 (en) 2019-08-28
PL3149480T3 (pl) 2019-06-28
PT3531133T (pt) 2023-11-07
DK3149480T3 (en) 2019-04-01
CA2948771C (en) 2023-10-17
HRP20231361T1 (hr) 2024-02-16
ES2961565T3 (es) 2024-03-12
EP4303585A3 (en) 2024-01-24
ES2715679T3 (es) 2019-06-05
EP3149480B1 (en) 2018-12-26
FI3531133T3 (fi) 2023-11-02
TR201903548T4 (tr) 2019-04-22
HUE042407T2 (hu) 2019-06-28
DK3531133T3 (da) 2023-11-06
PT3149480T (pt) 2019-03-21
LT3531133T (lt) 2023-11-10
EP4303585A2 (en) 2024-01-10
EP3531133B1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL247072A0 (en) Medical use
GB201403093D0 (en) Therapeutic compounds and their use
PL3122358T3 (pl) Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu
IL276733A (en) Use of Aribolin in cancer treatment
IL251371A0 (en) Cortexolone 17alpha-benzoate for use in the treatment of tumors
EP3104880A4 (en) Improved methods for the treatment of vascularizing cancers
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
EP3151821A4 (en) Marmelin analogs and methods of use in cancer treatment
EP3175244A4 (en) Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
EP3145525A4 (en) Use of microperoxidases for the treatment of carboxyhemoglobinemia
EP3110455A4 (en) Treatment of resistant lesions
SMT202300383T1 (it) Stratificazione del rischio di pazienti affetti da leucemia linfoblastica acuta da precursori b
GB201613350D0 (en) Treatment of hyperpigmentation
AU2014902075A0 (en) New Therapeutic Treatment Combination
EP3212202A4 (en) Use of therapeutic agents
AU2015902062A0 (en) New Therapeutic Treatment Combination
AU2014904330A0 (en) Use of therapeutic agents
EP3116996A4 (en) Treatment of resistant lesions
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use
GB201415302D0 (en) New therapeutic use
HK1232440A1 (en) Improved methods for the treatment of vascularizing cancers